×
About 3,398 results

ALLMedicine™ Brain Cancer Center

Research & Reviews  1,005 results

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT02644291

Jun 23rd, 2022 - The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing toler...

A Study of How Proton Beam Radiotherapy (PBRT) Affects Brain Function and Quality of Life in Children and Young Adults Undergoing Treatment for a Brain Tumor
https://clinicaltrials.gov/ct2/show/NCT05288439

Jun 21st, 2022 - The researchers are doing this study to find out if there are differences in the resting state brain networks of children and young adults (ages 6-21) after treatment with proton beam radiation therapy (PBRT). The researchers will use resting stat...

Brain cancer stem cells: resilience through adaptive plasticity and hierarchical hetero...
https://doi.org/10.1038/s41568-022-00486-x 10.1093/neuonc/noaa200 10.1016/B978-0-12-811161-1.00002-5 10.1016/j.nec.2020.06.001 10.1002/sctm.18-0123 10.1038/nature14432 10.1038/s41586-019-1419-5 10.1016/j.ccell.2017.02.009 10.1038/s41578-019-0135-y 10.1016/j.jocn.2018.05.002 10.1093/neuonc/noab106 10.1016/j.ccell.2021.01.006 10.4252/wjsc.v7.i1.27 10.1016/j.semcancer.2021.02.014 10.1016/j.stem.2018.11.011 10.1093/neuonc/noaa259 10.1038/s41588-021-00927-7 10.1001/jama.1917.02590330038011 10.1148/48.4.398 10.1126/science.959840 10.1111/j.1601-5223.1958.tb03493.x 10.1038/nature05236 10.1038/nature11287 10.1186/1476-4598-5-67 10.1158/0008-5472.CAN-06-1010 10.1016/j.cell.2013.02.021 10.1158/0008-5472.CAN-08-3886 10.1038/nature09624 10.1016/j.ccr.2009.12.020 10.1016/j.ccell.2017.06.003 10.1016/j.stem.2016.11.003 10.1038/s41593-018-0285-z 10.18632/oncotarget.18117 10.1158/0008-5472.CAN-10-4269 10.1101/gad.321968.118 10.1016/j.ccr.2010.03.020 10.1016/j.cell.2016.10.039 10.1158/0008-5472.CAN-16-1693 10.1016/j.celrep.2013.04.021 10.1038/s41388-019-1086-x 10.1016/j.ccr.2011.03.004 10.1002/stem.2053 10.1016/j.celrep.2016.06.092 10.1016/j.cub.2006.11.033 10.1016/j.stem.2009.01.007 10.1016/j.ccr.2010.10.023 10.1016/j.ccr.2013.04.008 10.1038/nm.4415 10.1038/s41467-021-21204-5 10.1038/nn.3510 10.1101/gad.261982.115 10.1136/jclinpath-2019-206246 10.1038/nature13109 10.1158/2159-8290.CD-20-1052 10.1158/2159-8290.CD-20-1066 10.1016/j.ccell.2015.04.002 10.1038/nature25169 10.1016/j.ccr.2005.09.001 10.1038/nature23666 10.1038/s41467-019-09853-z 10.1016/j.ccell.2020.04.001 10.1038/s43018-020-00150-z 10.1038/s41586-018-0389-3 10.1016/j.stem.2019.11.015 10.1038/s41593-018-0333-8 10.1016/j.ccell.2015.09.007 10.1016/j.ccell.2020.06.003 10.1016/j.stem.2021.01.016 10.1016/j.ccell.2021.01.005 10.1016/j.stem.2021.02.003 10.1038/s41467-020-17186-5 10.1016/j.cell.2019.06.024 10.1158/2159-8290.CD-19-0329 10.1038/s43018-020-00159-4 10.1158/2159-8290.CD-20-0219 10.1016/j.ccell.2021.05.002 10.1016/j.ccell.2017.05.005 10.1038/nature22973 10.1016/j.ccell.2019.07.009 10.1038/s41586-019-1158-7 10.1016/j.ccell.2020.06.004 10.1016/j.celrep.2020.108023 10.1126/scitranslmed.abc0497 10.1016/j.ccell.2015.07.013 10.1038/ng.3590 10.1038/ng.3806 10.1016/j.ccell.2019.02.007 10.1038/s41591-018-0156-x 10.1038/s41586-019-1775-1 10.1038/s41586-019-0882-3 10.1038/s41556-021-00639-4 10.1126/science.1241328 10.1038/nature21356 10.1038/s41588-018-0105-0 10.1016/j.cell.2019.10.039 10.1016/j.tips.2018.12.004 10.1007/978-1-4614-1445-2_8 10.18632/oncotarget.22514 10.1016/j.stem.2014.04.007 10.1593/neo.13662 10.1016/j.ebiom.2019.03.064 10.1016/j.yexcr.2018.12.010 10.1186/s13059-020-02085-1 10.1038/s41419-019-2200-2 10.1158/1541-7786.MCR-19-0669 10.1016/j.stem.2019.06.004 10.1038/nature16071 10.1016/j.stem.2018.03.011 10.1038/nature14363 10.1016/j.stem.2017.10.005 10.1038/ncb3272 10.1016/j.ccell.2016.09.008 10.1016/j.biopha.2020.110086 10.1038/nature09557 10.1016/j.stem.2017.10.002 10.1016/j.cell.2015.04.012 10.1038/nature24014 10.1038/s41586-019-1563-y 10.1038/s41586-019-1564-x 10.1038/s41586-020-1952-2 10.1038/s41467-021-22225-w 10.1038/s41467-020-20225-w 10.1038/s41590-017-0022-x 10.1016/j.cell.2020.05.007 10.1038/s41593-020-00789-y 10.1158/0008-5472.CAN-15-2386 10.1038/ncb3090 10.1038/nm.3337 10.1126/science.aad3018 10.1016/j.ccell.2019.05.003 10.1158/2159-8290.CD-19-0400 10.1038/s41593-019-0370-y 10.1016/j.cell.2021.03.023 10.1038/s41591-018-0095-6 10.1158/1078-0432.CCR-09-2730 10.1371/journal.pone.0169932 10.1038/s41591-018-0135-2 10.1016/j.cell.2021.01.022 10.1016/j.cell.2020.04.055 10.1038/nature05349 10.1016/j.ccr.2007.12.005 10.1158/2159-8290.CD-19-0215 10.1016/j.ccell.2018.08.003 10.1084/jem.20171093 10.1056/NEJMoa1610497 10.1001/jamaoncol.2017.0184 10.1158/0008-5472.CAN-17-1788 10.1093/neuonc/noz117 10.1038/mt.2012.210 10.1016/j.stem.2020.04.008 10.1016/j.cell.2016.01.011 10.1158/2159-8290.CD-20-1243 10.1038/s41586-018-0810-y 10.3389/fonc.2021.672508 10.1038/367645a0 10.1073/pnas.0530291100 10.1038/nature03128 10.1158/0008-5472.CAN-05-2018 10.1038/nature05372 10.1038/nature05384 10.1158/0008-5472.CAN-06-2030 10.1016/j.cell.2016.11.037 10.1016/j.stem.2014.02.002 10.1038/s41591-020-01195-4 10.1016/j.cell.2021.12.043 10.1126/science.1228522 10.1016/j.semcancer.2019.09.007 10.1016/j.cell.2018.11.046 10.1038/nature15260 10.1038/nature20785 10.1158/1541-7786.MCR-20-0863 10.1038/nature20609 10.1016/j.cell.2016.02.025 10.1038/s41591-019-0750-6 10.1016/j.stem.2020.02.008 10.1038/s43018-019-0006-x 10.1038/s41556-018-0138-8 10.1038/s41388-019-0959-3 10.1158/0008-5472.CAN-17-2994 10.1038/nature18268 10.1016/j.cell.2014.01.040 10.1038/s41586-019-1576-6 10.1038/s43018-021-00183-y 10.1038/s41586-020-2969-2 10.1038/nature20791 10.1038/s41586-019-1847-2 10.1016/j.cell.2014.11.025 10.1158/0008-5472.CAN-14-2268 10.1126/science.aaw6985 10.1158/0008-5472.CAN-15-2402 10.1016/j.celrep.2018.03.105 10.1038/s41592-018-0070-7 10.1016/j.celrep.2019.02.063 10.1158/2159-8290.CD-20-0057 10.1038/s41467-019-13989-3 10.1016/j.cell.2019.11.036 10.1038/s41596-020-0402-9 10.1002/adma.201806590 10.1038/s41422-020-0338-1 10.1002/smll.202006050 10.1038/s41551-019-0363-x 10.1016/j.isci.2020.101365
Nature Reviews. Cancer; Gimple RC, Yang K et. al.

Jun 18th, 2022 - Malignant brain tumours are complex ecosystems containing neoplastic and stromal components that generate adaptive and evolutionarily driven aberrant tissues in the central nervous system. Brain cancers are cultivated by a dynamic population of st...

Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance a...
https://doi.org/10.1038/s41416-022-01865-9 10.1056/NEJM200101113440207 10.1056/NEJMoa043330 10.1016/j.pharmthera.2015.05.005 10.1016/j.critrevonc.2015.05.013 10.3389/fphys.2018.00170 10.4103/2152-7806.137196 10.1097/PPO.0b013e318244d7eb 10.1093/neuonc/nou087 10.2147/MDER.S214152 10.1158/0008-5472.CAN-04-0083 10.1186/1756-9966-28-51 10.21873/anticanres.12590 10.1002/cam4.861 10.1038/srep18046 10.21873/anticanres.11166 10.18632/oncotarget.26344 10.1080/15368378.2019.1625784 10.1158/1078-0432.CCR-17-1117 10.1038/s41416-020-01136-5 10.1002/lary.20210 10.3109/00016489.2012.659752 10.1177/1756284820923220 10.1111/iwj.12805 10.1007/s10261-011-0013-7 10.1159/000101745 10.1371/journal.pone.0190082 10.1088/1757-899X/88/1/012036 10.1039/D0MO00087F 10.1093/nar/gkv468 10.1093/nar/gkg034 10.1177/1087057114521867 10.1371/journal.pone.0035577 10.1200/JCO.2007.11.5964 10.1158/0008-5472.CAN-10-3213 10.1158/0008-5472.CAN-18-3631 10.1038/nrc1714 10.1038/nrm2858 10.1093/carcin/bgp268 10.1038/nature12625 10.1101/SQB.1991.056.01.076 10.1126/science.1210214 10.1038/nature14493 10.1038/ncomms12619 10.1126/science.297.5581.544 10.1038/nrm2718 10.1146/annurev-cellbio-101011-155807 10.7861/clinmedicine.14-6-s33 10.4161/cc.4.5.1687 10.1038/ng1861 10.1158/1078-0432.CCR-13-0645 10.1073/pnas.1114033109 10.1016/j.ceb.2011.11.003 10.1038/nrm2163 10.1038/nrg2466 10.1038/onc.2012.576 10.1038/emboj.2009.173 10.1016/j.devcel.2010.11.011 10.1038/nrm3115 10.1146/annurev.bi.55.070186.005443
British Journal of Cancer; Catanzaro D, Milani G et. al.

Jun 18th, 2022 - Glioblastoma is the most aggressive form of brain cancer, characterised by high proliferation rates and cell invasiveness. Despite advances in surgery and radio-chemotherapy, patients continue to have poor prognoses, with a survival rate of 14-15 ...

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
https://clinicaltrials.gov/ct2/show/NCT03423628

Jun 13th, 2022 - This first time-in patients (FTIP), open-label, multicentre study of AZD1390 will be conducted in the United States and in the United Kingdom, and it consists of three treatment arms: Arm A, B, C. This Phase 1 study will assess safety and tolerabi...

see more →

Guidelines  1 results

Clinical practice guidelines for the management of adult diffuse gliomas.
https://doi.org/10.1016/j.canlet.2020.10.050
Cancer Letters; Jiang T, Nam DH et. al.

Nov 10th, 2020 - To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-Chi...

see more →

Clinicaltrials.gov  107 results

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT02644291

Jun 23rd, 2022 - The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing toler...

A Study of How Proton Beam Radiotherapy (PBRT) Affects Brain Function and Quality of Life in Children and Young Adults Undergoing Treatment for a Brain Tumor
https://clinicaltrials.gov/ct2/show/NCT05288439

Jun 21st, 2022 - The researchers are doing this study to find out if there are differences in the resting state brain networks of children and young adults (ages 6-21) after treatment with proton beam radiation therapy (PBRT). The researchers will use resting stat...

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
https://clinicaltrials.gov/ct2/show/NCT03423628

Jun 13th, 2022 - This first time-in patients (FTIP), open-label, multicentre study of AZD1390 will be conducted in the United States and in the United Kingdom, and it consists of three treatment arms: Arm A, B, C. This Phase 1 study will assess safety and tolerabi...

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
https://clinicaltrials.gov/ct2/show/NCT03107780

Jun 8th, 2022 - PRIMARY OBJECTIVES: I. Determine the concentration and variability in concentration of navtemadlin (AMG 232 [KRT 232]) in brain and brain-associated tissue in patients with recurrent glioblastoma (GBM). (Part 1) II. Determine the maximum tolerated...

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05130840

Jun 8th, 2022 - The researchers doing this study think that performing scans of the brain and testing cerebrospinal fluid (CSF) in people with HER2-positive breast cancer may be an effective way of identifying the early onset of CNS metastases (such as brain canc...

see more →

News  244 results

US Senate Passes Bill to Help Veterans Exposed to Toxic Burn Pits
https://www.medscape.com/viewarticle/975760

Jun 17th, 2022 - WASHINGTON (Reuters) - A major bill expanding health care and benefits for veterans exposed to toxic military burn pits in Iraq and Afghanistan passed the U.S. Senate on Thursday, as senators praised their bipartisan work on one of the few issues ...

Targeted Therapy an 'Important Advance' in Childhood Glioma
https://www.medscape.com/viewarticle/975107

Jun 6th, 2022 - CHICAGO —Targeted therapy achieved significantly higher responses rates and longer progression-free survival (PFS) when compared with standard chemotherapy in pediatric patients with BRAF V600-mutant low-grade gliomas, even those as young as 1 yea...

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Cancer: Seeds of Destruction Developed To Attack Brain Tumour Cells
https://www.medscape.com/viewarticle/967583

Feb 3rd, 2022 - Researchers from University College London (UCL) have developed a new technique that combines thermal ablation of cancer cells with magnetic resonance navigation (MRN) to deliver implanted ferromagnetic thermoseeds to the precise site of a brain t...

Biden's 'Cancer Moonshot' About to Be Relaunched
https://www.medscape.com/viewarticle/967810

Feb 3rd, 2022 - The "Cancer Moonshot" is about to be relaunched! In a White House briefing, President Joe Biden announced that he is "reigniting" the initiative he spearheaded when he was Vice President during the Obama administration. During the livestreamed eve...

see more →

Patient Education  2 results see all →